{"entity":{"id":"cdkn2b","kind":"target","name":"CDKN2B","aka":["cyclin dependent kinase inhibitor 2B","Cyclin-dependent kinase 4 inhibitor B","P15","MTS2","INK4B","TP15","CDK4I","p15INK4b"],"tldr":"CDKN2B (Cyclin-dependent kinase 4 inhibitor B) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma, Breast cancer and 5 more.","summary":"Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest.\n\nCIViC holds 8 clinical evidence items and 0 assertions across 5 variants, naming Palbociclib, Trametinib, Bevacizumab and Vemurafenib and others. Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes genetic literature 0.30, affected pathway 0.76, literature 0.98, genetic association 0.70, somatic mutation 0.62).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:1788","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788"},{"label":"UniProt P42772","url":"https://www.uniprot.org/uniprotkb/P42772/entry"},{"label":"NCBI Gene 1030","url":"https://www.ncbi.nlm.nih.gov/gene/1030"},{"label":"Ensembl ENSG00000147883","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147883"}],"tags":["cancer-genes-wave"],"related":["civic","open-targets"],"cancers":["pancreatic","rcc","breast-cancer","skin-cancer","cholangiocarcinoma","ewing-sarcoma","apl","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["sclc-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 9 therapies; CIViC holds 8 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Ganglioglioma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CDKN2B","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:1788","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1788","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P42772","url":"https://www.uniprot.org/uniprotkb/P42772/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CDKN2B","url":"https://civicdb.org/features/916","note":"8 evidence items, 0 assertions, 5 variants; diseases: Pancreatic Cancer, Cholangiocarcinoma, Ewing Sarcoma, Renal Cell Carcinoma, Acute Promyelocytic Leukaemia and 2 more (GraphQL API, CC0)"},{"label":"Open Targets ENSG00000147883","url":"https://platform.opentargets.org/target/ENSG00000147883/associations","note":"association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: skin cancer 0.51, basal cell carcinoma 0.50, breast cancer 0.60 (GraphQL API, CC0)"}],"hgnc":"HGNC:1788","ensembl":"ENSG00000147883","uniprot":"P42772","entrez":"1030","biology":"Interacts strongly with CDK4 and CDK6. Potent inhibitor. Potential effector of TGF-beta induced cell cycle arrest. Location: Cytoplasm (UniProt). Locus 9p21.3 (HGNC).","whereFound":["Pancreatic ductal adenocarcinoma: CIViC evidence names this disease","Renal cell carcinoma: CIViC evidence names this disease","Breast cancer: Open Targets association 0.60 with breast cancer (MONDO_0007254)","Skin cancer: Open Targets association 0.51 with skin cancer (MONDO_0002898)","Biliary tract cancer: CIViC evidence names this disease","Ewing sarcoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/cdkn2b/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/"},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}],"pathway":[{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/"}]}}